Regulus Therapeutics Inc. (NASDAQ:RGLS) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have been given an average recommendation of “Moderate Buy” by the six brokerages that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $10.80.

A number of research firms have issued reports on RGLS. StockNews.com upgraded shares of Regulus Therapeutics to a “sell” rating in a report on Tuesday, September 17th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of Regulus Therapeutics in a report on Monday, November 11th.

Regulus Therapeutics Trading Down 1.2 %

Shares of NASDAQ:RGLS opened at $1.62 on Wednesday. The stock has a market capitalization of $106.11 million, a PE ratio of -1.51 and a beta of 1.61. Regulus Therapeutics has a 1 year low of $1.08 and a 1 year high of $3.79. The firm has a fifty day moving average price of $1.52 and a 200 day moving average price of $1.70.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). On average, sell-side analysts forecast that Regulus Therapeutics will post -0.88 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in RGLS. Vanguard Group Inc. raised its position in shares of Regulus Therapeutics by 158.4% during the first quarter. Vanguard Group Inc. now owns 740,215 shares of the biopharmaceutical company’s stock valued at $2,132,000 after buying an additional 453,784 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of Regulus Therapeutics during the second quarter valued at about $352,000. Rhumbline Advisers acquired a new position in shares of Regulus Therapeutics during the second quarter valued at about $136,000. Renaissance Technologies LLC raised its position in shares of Regulus Therapeutics by 56.4% during the second quarter. Renaissance Technologies LLC now owns 118,100 shares of the biopharmaceutical company’s stock valued at $211,000 after buying an additional 42,600 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in shares of Regulus Therapeutics during the third quarter valued at about $33,000. Institutional investors and hedge funds own 92.38% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.